CHINOOK THERAPEUTICS INC's ticker is KDNY and the CUSIP is 16961L106. A total of 139 filers reported holding CHINOOK THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $163,793,718 | +79.5% | 4,263,241 | +8.1% | 0.01% | +66.7% |
| Q1 2023 | $91,269,778 | -11.9% | 3,942,539 | -0.3% | 0.00% | 0.0% |
| Q4 2022 | $103,614,216 | +44.3% | 3,954,741 | +8.3% | 0.00% | +50.0% |
| Q3 2022 | $71,785,000 | +23.2% | 3,651,299 | +9.6% | 0.00% | 0.0% |
| Q2 2022 | $58,279,000 | +16.6% | 3,332,130 | +9.1% | 0.00% | +100.0% |
| Q1 2022 | $49,980,000 | +2.6% | 3,054,997 | +2.2% | 0.00% | 0.0% |
| Q4 2021 | $48,733,000 | +50.5% | 2,987,931 | +17.8% | 0.00% | 0.0% |
| Q3 2021 | $32,375,000 | -7.2% | 2,537,226 | +2.7% | 0.00% | 0.0% |
| Q2 2021 | $34,883,000 | +59.5% | 2,470,469 | +75.5% | 0.00% | 0.0% |
| Q1 2021 | $21,870,000 | -2.1% | 1,407,336 | -0.1% | 0.00% | 0.0% |
| Q4 2020 | $22,336,000 | – | 1,408,282 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 5,161,888 | $135,241,466 | 29.11% |
| Octagon Capital Advisors LP | 2,551,703 | $66,854,619 | 10.41% |
| Affinity Asset Advisors, LLC | 818,035 | $21,432,517 | 8.40% |
| Frazier Life Sciences Management, L.P. | 4,345,559 | $113,853,646 | 7.08% |
| Saturn V Capital Management LP | 423,177 | $6,728,298 | 5.58% |
| Altium Capital Management LP | 385,000 | $10,087,000 | 5.13% |
| Deep Track Capital, LP | 3,000,000 | $78,600,000 | 3.30% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 340,389 | $8,914,788 | 2.75% |
| Vivo Capital, LLC | 872,151 | $22,850 | 2.63% |
| Nan Fung Group Holdings Ltd | 113,950 | $2,985,490 | 2.06% |